Safety and Efficacy of CMX001 as Salvage Therapy for Severe Adenovirus Infections in Immunocompromised Patients

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 731-738

  Florescu, Diana F ^a   Pergam, Steven A ^b,c   Neely, Michael N ^d   Qiu, Fang ^a   Johnston, Christine ^b,c   Way, SingSing ^e   Sande, Jane ^f   Lewinsohn, Deborah A ^g   Guzman Cottrill, Judith A ^g   Graham, Michael L ^h   Papanicolaou, Genovefa ⁱ   Kurtzberg, Joanne ^j   Rigdon, Joseph ^k   Painter, Wendy ^l   Mommeja Marin, Herve ^l   Lanier, Randall ^l   Anderson, Maggie ^l   van der Horst, Charles ^k  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l Chimerix Inc   (United States)

more..

Author keywords

Allogeneic stem cell transplant; Nephrotoxicity; Small bowel transplant; Therapeutic option; Treatment; Virologic response

Indexed keywords

CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER;

ADENOVIRUS INFECTION; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; LYMPHOCYTE COUNT; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOSINE; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84859872029     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.09.007     Document Type: Article

References (45)

1. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008, 21:704-715.
2. Tang Q., Lundholm-Beauchamp U., Ginsberg H.S. Spontaneous occurrence of early region 1A reiteration mutants of type 5 adenovirus in persistently infected human T-lymphocytes. Virology 1997, 230:281-291.
3. Garnett C.T., Erdman D., Xu W., et al. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002, 76:10608-10616.
4. Hale G.A., Heslop H.E., Krance R.A., et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 1999, 23:277-282.
5. La Rosa A.M., Champlin R.E., Mirza N., et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001, 32:871-876.
6. Kojaoghlanian T., Flomenberg P., Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003, 13:155-171.
7. van Tol M.J., Claas E.C., Heemskerk B., et al. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant 2005, 35(Suppl 1):S73-S76.
8. Shields A.F., Hackman R.C., Fife K.H., et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 1985, 312:529-533.
9. Wasserman R., August C.S., Plotkin S.A. Viral infections in pediatric bone marrow transplant patients. Pediatr Infect Dis J 1988, 7:109-115.
10. Ljungman P., Gleaves C.A., Meyers J.D. Respiratory virus infection in immunocompromised patients. Bone Marrow Transplant 1989, 4:35-40.
11. Flomenberg P., Babbitt J., Drobyski W.R., et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994, 169:775-781.
12. Blanke C., Clark C., Broun E.R., et al. Evolving pathogens in allogeneic bone marrow transplantation: increased fatal adenoviral infections. Am J Med 1995, 99:326-328.
13. Howard D.S., Phillips G.L., Reece D.E., et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999, 29:1494-1501.
14. Venard V., Carret A., Corsaro D., et al. Genotyping of adenoviruses isolated in an outbreak in a bone marrow transplant unit shows that diverse strains are involved. J Hosp Infect 2000, 44:71-74.
15. Hoffman J.A., Shah A.J., Ross L.A., et al. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001, 7:388-394.
16. Bordigoni P., Carret A.S., Venard V., et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001, 32:1290-1297.
17. Echavarria M., Forman M., van Tol M.J., et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001, 358:384-385.
18. Leruez-Ville M., Minard V., Lacaille F., et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004, 38:45-52.
19. Kampmann B., Cubitt D., Walls T., et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Haematol 2005, 130:595-603.
20. Yusuf U., Hale G.A., Carr J., et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006, 81:1398-1404.
21. Kroes A.C., de Klerk E.P., Lankester A.C., et al. Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. J Clin Virol 2007, 38:341-347.
22. Kalpoe J.S., van der Heiden P.L., Barge R.M., et al. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning. Eur J Haematol 2007, 78:314-321.
23. Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 2006, 82:S9-S14.
24. Pinchoff R.J., Kaufman S.S., Magid M.S., et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation 2003, 76:183-189.
25. McLaughlin G.E., Delis S., Kashimawo L., et al. Adenovirus infection in pediatric liver and intestinal transplant recipients: utility of DNA detection by PCR. Am J Transplant 2003, 3:224-228.
26. Florescu D.F., Islam M.K., Mercer D.F., et al. Adenovirus infections in pediatric small bowel transplant recipients. Transplantation 2010, 90:198-204.
27. Jacobson M.A. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:105-114.
28. Gilead Sciences. VISTIDE (cidofovir injection). Available from: Accessed February 2, 2011. http://www.gilead.com/pdf/vistide.pdf.
29. Ciesla S.L., Trahan J., Wan W.B., et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003, 59:163-171.
30. Aldern K.A., Ciesla S.L., Winegarden K.L., et al. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003, 63:678-681.
31. Painter G.R., Hostetler K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 2004, 22:423-427.
32. Hostetler K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009, 82:A84-98.
33. Trost L, Tippin TK, Anderson MT, et al. Compromised renal function does not affect the pharmacokinetics of CMX001 in patients with severe double-stranded DNA virus infections. 50th ICAAC, Boston, MA, September 12-15, 2010; A1-2017a.
34. US Food and Drug Administration. Emergency investigational new drug (EIND) applications for antimicrobial products. Available from: Accessed February 2, 2011. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm090039.htm.
35. Ljungman P., Ribaud P., Eyrich M., et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003, 31:481-486.
36. Unnebrink K., Windeler J. Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases. Stat Med 2001, 20:3931-3946.
37. Baldwin A., Kingman H., Darville M., et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000, 26:1333-1338.
38. Lion T., Baumgartinger R., Watzinger F., et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003, 102:1114-1120.
39. Chakrabarti S., Mautner V., Osman H., et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002, 100:1619-1627.
40. Feuchtinger T., Lucke J., Hamprecht K., et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005, 128:503-509.
41. Feuchtinger T., Richard C., Pfeiffer M., et al. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update. Clin Pediatr 2006, 217:339-344.
42. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004, 23:583-588.
43. Nagafuji K., Aoki K., Henzan H., et al. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004, 34:909-914.
44. VISTIDE prescribing information 2002, Gilead Sciences, Foster City, CA.
45. Symeonidis N., Jakubowski A., Pierre-Louis S., et al. Invasive adenoviral infections in T cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007, 9:108-113.